Department of Psychiatry, University of Utah & Huntsman Mental Health Institute, Salt Lake City, UT, 84112, USA.
Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania and Mental Illness Research, Education and Clinical Center, Crescenz VAMC, Philadelphia, PA, 19104, USA.
Neuropsychopharmacology. 2022 Sep;47(10):1784-1790. doi: 10.1038/s41386-022-01325-1. Epub 2022 May 11.
Major depressive disorder (MDD) and opioid use disorder (OUD) are common, potentially fatal, polygenic disorders that are moderately heritable and often co-occur. We examined the unique and shared associations of polygenic risk scores (PRS) for these disorders with µ-opioid receptor (MOR) concentration and endogenous opioid response during a stressful stimulus. Participants were 144 healthy European-ancestry (EA) subjects (88 females) who underwent MOR quantification scans with [C]carfentanil and PET and provided DNA for genotyping. MOR non-displaceable binding potential (BP) was measured in 5 regions of interest (ROIs) related to mood and addiction. We examined associations of PRS both at baseline and following opioid release calculated as the ratio of baseline and stress-challenge scans, first in the entire sample and then separately by sex. MOR availability at baseline was positively associated with MDD PRS in the amygdala and ventral pallidum. MDD and OUD PRS were significantly associated with stress-induced opioid system activation in multiple ROIs, accounting for up to 14.5% and 5.4%, respectively, of the variance in regional activation. The associations were most robust among females, where combined they accounted for up to 25.0% of the variance among the ROIs. We conclude that there is a pathophysiologic link between polygenic risk for MDD and OUD and opioid system activity, as evidenced by PRS with unique and overlapping regional associations with this neurotransmitter system. This link could help to explain the high rate of comorbidity of MDD and OUD and suggests that opioid-modulating interventions could be useful in treating MDD and OUD, both individually and jointly.
重度抑郁症(MDD)和阿片类药物使用障碍(OUD)是常见的、潜在致命的、多基因疾病,具有中度遗传性,且经常同时发生。我们研究了这些疾病的多基因风险评分(PRS)与应激刺激期间µ-阿片受体(MOR)浓度和内源性阿片反应的独特和共同关联。参与者是 144 名健康的欧洲血统(EA)受试者(88 名女性),他们接受了 [C]carfentanil 和 PET 的 MOR 定量扫描,并提供了用于基因分型的 DNA。在与情绪和成瘾相关的 5 个感兴趣区域(ROI)中测量了 MOR 不可置换结合潜力(BP)。我们在整个样本中首先,然后按性别分别检查了 PRS 在基线和阿片类药物释放后的关联,阿片类药物释放计算为基线和应激挑战扫描的比值。基线时的 MOR 可用性与杏仁核和腹侧苍白球中的 MDD PRS 呈正相关。MDD 和 OUD PRS 与多个 ROI 中的应激诱导的阿片系统激活显著相关,分别解释了区域激活差异的 14.5%和 5.4%。这些关联在女性中最为稳健,其中两者结合起来,占 ROI 之间差异的 25.0%。我们得出的结论是,MDD 和 OUD 的多基因风险与阿片系统活性之间存在病理生理学联系,这一点可以通过与该神经递质系统具有独特和重叠的区域关联的 PRS 来证明。这种联系可以帮助解释 MDD 和 OUD 共病率高的原因,并表明阿片类药物调节干预可能对单独和联合治疗 MDD 和 OUD 有用。